PUBLIC SUMMARY DOCUMENT Product: AGOMELATINE, tablet, 25mg, Valdoxan® Sponsor: Servier Laboratories (Australia) Pty Ltd Date of PBAC Consideration: March[removed]Purpose of Application

First Page		Document Content
Date: 2015-03-06 00:23:40 Selective serotonin reuptake inhibitors Acetamides Organofluorides Treatment of bipolar disorder Antidepressants Agomelatine Venlafaxine Fluoxetine Serotonin–norepinephrine reuptake inhibitor Chemistry Organic chemistry Psychiatry		PUBLIC SUMMARY DOCUMENT Product: AGOMELATINE, tablet, 25mg, Valdoxan® Sponsor: Servier Laboratories (Australia) Pty Ltd Date of PBAC Consideration: March[removed]Purpose of Application Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 383,86 KB Share Document on Facebook

	Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No DocID: 1rqYi - View Document
	Microsoft WordDOCX DocID: 1rnqZ - View Document
	Beilage 1: Arzneimittelmonographien DocID: 1rinj - View Document
	SAFETY DATA SHEET Page 1 of Total 6 Date of Issue: August 2016 SDS No. FMC/RAD/1 SECTION 1 DocID: 1rdYu - View Document
	imatinib and colon cancer. imatinib availability imatinib and cml imatinib and tight junction cancer imatinib prostate dercum and imatinib zactima plus imatinib DocID: 1rdbp - View Document